Terms: = Bone cancer AND TERT, EST2, Q8NG46, Q8N6C3, Q2XS35, O14783, O14746, 7015, hEST2, TCS1, TRT, TP2 AND Treatment
62 results:
1. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; García-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyż J; Fernández De Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Wu B; Yu Y; Shen Z; Chan WY; Schneider J; Allewelt H; Cohen A; Dimopoulos MA
Blood Adv; 2024 Apr; 8(7):1639-1650. PubMed ID: 38315878
[TBL] [Abstract] [Full Text] [Related]
2. EMAS position statement: Testosterone replacement therapy in older men.
Kanakis GA; Pofi R; Goulis DG; Isidori AM; Armeni E; Erel CT; Fistonić I; Hillard T; Hirschberg AL; Meczekalski B; Mendoza N; Mueck AO; Simoncini T; Stute P; van Dijken D; Rees M; Lambrinoudaki I
Maturitas; 2023 Dec; 178():107854. PubMed ID: 37845136
[TBL] [Abstract] [Full Text] [Related]
3. Adult granulosa cell tumor of the testis with malignant tendency: A case report with genetic analysis using high-throughput sequencing.
Deng L; Zeng J; Qiu JF; Yang LH; Ma J
Medicine (Baltimore); 2023 Aug; 102(32):e34523. PubMed ID: 37565864
[TBL] [Abstract] [Full Text] [Related]
4. Effect of 12-months testosterone replacement therapy on bone mineral density and markers of bone turnover in testicular cancer survivors - results from a randomized double-blind trial.
Jørgensen PL; Kreiberg M; Jørgensen N; Juul A; Oturai PS; Dehlendorff C; Lauritsen J; Wagner T; Rosenvilde J; Daugaard G; Medici CR; Jørgensen NR; Bandak M
Acta Oncol; 2023 Jul; 62(7):689-695. PubMed ID: 37151105
[TBL] [Abstract] [Full Text] [Related]
5. Distinct mutational pattern of T-cell large granular lymphocyte leukemia combined with pure red cell aplasia: low mutational burden of STAT3.
Park S; Yun J; Choi SY; Jeong D; Gu JY; Lee JS; Seong MW; Chang YH; Yun H; Kim HK
Sci Rep; 2023 May; 13(1):7280. PubMed ID: 37142644
[TBL] [Abstract] [Full Text] [Related]
6. Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia.
Garcia-Sanz R; Varettoni M; Jiménez C; Ferrero S; Poulain S; San-Miguel JF; Guerrera ML; Drandi D; Bagratuni T; McMaster M; Roccaro AM; Roos-Weil D; Leiba M; Li Y; Qiu L; Hou J; De Larrea CF; Castillo JJ; Dimopoulos M; Owen RG; Treon SP; Hunter ZR
Semin Hematol; 2023 Mar; 60(2):90-96. PubMed ID: 37099028
[TBL] [Abstract] [Full Text] [Related]
7. [Differential diagnostic between hepatocellular carcinoma and hepatoid carcinoma with bone metastasis revelation: What tools can be used?].
Neyrand S; Bringuier PP; Benzerdjeb N; Hervieu V; Fenouil T
Ann Pathol; 2023 Sep; 43(5):407-411. PubMed ID: 36822899
[TBL] [Abstract] [Full Text] [Related]
8. Combined analysis of PHOX2B at two time points and its value for further risk stratification in high-risk neuroblastoma.
Yue Z; Gao C; Xing T; Zhao W; Duan C; Wang X; Jin M; Su Y
Pediatr Blood Cancer; 2023 May; 70(5):e30261. PubMed ID: 36815592
[TBL] [Abstract] [Full Text] [Related]
9. Pan-cancer analysis of tert and Validation in Osteosarcoma Cell Lines.
Xie L; Yin W; Tang F; He M
Biochem Biophys Res Commun; 2023 Jan; 639():106-116. PubMed ID: 36476950
[TBL] [Abstract] [Full Text] [Related]
10. Real-world utility of early measurable residual disease assessments by multi-parametric flow cytometry in adult patients with B-lymphoblastic leukemia receiving Hyper-CVAD induction chemotherapy.
Nedumannil R; Ritchie D; Bajel A; Ng AP; Harrison SJ; Westerman D
Eur J Haematol; 2023 Feb; 110(2):168-176. PubMed ID: 36321745
[TBL] [Abstract] [Full Text] [Related]
11. Prospective longitudinal evaluation of treatment-related toxicity and health-related quality of life during the first year of treatment for pediatric acute lymphoblastic leukemia.
Schilstra CE; McCleary K; Fardell JE; Donoghoe MW; McCormack E; Kotecha RS; Lourenco RA; Ramachandran S; Cockcroft R; Conyers R; Cross S; Dalla-Pozza L; Downie P; Revesz T; Osborn M; Alvaro F; Wakefield CE; Marshall GM; Mateos MK; Trahair TN
BMC Cancer; 2022 Sep; 22(1):985. PubMed ID: 36109702
[TBL] [Abstract] [Full Text] [Related]
12. A genetic model for central chondrosarcoma evolution correlates with patient outcome.
Cross W; Lyskjær I; Lesluyes T; Hargreaves S; Strobl AC; Davies C; Waise S; Hames-Fathi S; Oukrif D; Ye H; Amary F; Tirabosco R; Gerrand C; Baker T; Barnes D; Steele C; Alexandrov L; Bond G; ; Cool P; Pillay N; Van Loo P; Flanagan AM
Genome Med; 2022 Aug; 14(1):99. PubMed ID: 36042521
[TBL] [Abstract] [Full Text] [Related]
13. Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets.
Nacev BA; Sanchez-Vega F; Smith SA; Antonescu CR; Rosenbaum E; Shi H; Tang C; Socci ND; Rana S; Gularte-Mérida R; Zehir A; Gounder MM; Bowler TG; Luthra A; Jadeja B; Okada A; Strong JA; Stoller J; Chan JE; Chi P; D'Angelo SP; Dickson MA; Kelly CM; Keohan ML; Movva S; Thornton K; Meyers PA; Wexler LH; Slotkin EK; Glade Bender JL; Shukla NN; Hensley ML; Healey JH; La Quaglia MP; Alektiar KM; Crago AM; Yoon SS; Untch BR; Chiang S; Agaram NP; Hameed MR; Berger MF; Solit DB; Schultz N; Ladanyi M; Singer S; Tap WD
Nat Commun; 2022 Jun; 13(1):3405. PubMed ID: 35705560
[TBL] [Abstract] [Full Text] [Related]
14. Fast beta-emitter Monte Carlo simulations and full patient dose calculations of targeted radionuclide therapy: introducing egs_mird.
Martinov MP; Opara C; Thomson RM; Lee TY
Med Phys; 2022 Sep; 49(9):6137-6149. PubMed ID: 35650012
[TBL] [Abstract] [Full Text] [Related]
15. Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid cancer With Papillary Histology.
Soe MH; Chiang JM; Flavell RR; Khanafshar E; Mendoza L; Kang H; Liu C
J Clin Endocrinol Metab; 2022 Jul; 107(8):e3206-e3216. PubMed ID: 35556126
[TBL] [Abstract] [Full Text] [Related]
16. Genome-wide association study on 13 167 individuals identifies regulators of blood CD34+cell levels.
Lopez de Lapuente Portilla A; Ekdahl L; Cafaro C; Ali Z; Miharada N; Thorleifsson G; Žemaitis K; Lamarca Arrizabalaga A; Thodberg M; Pertesi M; Dhapola P; Bao E; Niroula A; Bali D; Norddahl G; Ugidos Damboriena N; Sankaran VG; Karlsson G; Thorsteinsdottir U; Larsson J; Stefansson K; Nilsson B
Blood; 2022 Mar; 139(11):1659-1669. PubMed ID: 35007327
[TBL] [Abstract] [Full Text] [Related]
17. Analysis of the growing public interest in selective androgen receptor modulators.
Efimenko IV; Chertman W; Masterson TA; Dubin JM; Ramasamy R
Andrologia; 2021 Dec; 53(11):e14238. PubMed ID: 34510504
[TBL] [Abstract] [Full Text] [Related]
18. Comparison of Outcomes of Myeloablative Allogeneic Stem Cell Transplantation for Pediatric Patients with bone Marrow Failure, Myelodysplastic Syndrome and Acute Myeloid Leukemia with and without Germline GATA2 Mutations.
Hofmann I; Avagyan S; Stetson A; Guo D; Al-Sayegh H; London WB; Lehmann L
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1124-1130. PubMed ID: 32088370
[TBL] [Abstract] [Full Text] [Related]
19. Salutary Response to Targeted Therapy in Anaplastic Thyroid cancer.
Fazeli S; Paal E; Maxwell JH; Burman KD; Nylen ES; Khosla SG
J Investig Med High Impact Case Rep; 2019; 7():2324709619890942. PubMed ID: 31766881
[No Abstract] [Full Text] [Related]
20. Peculiar pathological, radiological and clinical features of skull-base de-differentiated chordomas. Results from a referral centre case-series and literature review.
Asioli S; Zoli M; Guaraldi F; Sollini G; Bacci A; Gibertoni D; Ricci C; Morandi L; Pasquini E; Righi A; Mazzatenta D
Histopathology; 2020 Apr; 76(5):731-739. PubMed ID: 31652338
[TBL] [Abstract] [Full Text] [Related]
[Next]
